exploratory study on lactibiane topic ad on skin flora and barrier reinforcement in mild to moderate atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this exploratory study aims to evaluate the impact of a cosmetic product (lactibiane topic ad) vs placebo on skin flora and skin reinforcement barrier in mild to moderate atopic dermatitis using biometrological, biological and clinical parameters.


Eligibility criteria:
inclusion criteria: * subject diagnosed with mild to moderate ad defined as scorad≤40 (eichenfield et al. jaad 2014). * subject with at least two symmetric ad lesions with comparable severity: located either on upper extremities (left and right arms except hands) or lower extremities (left and right legs except feet), with an erythema ≥ 1 (mild to severe intensity), with a lesional area score ≥ 4 on both lesions with an authorized delta of two points between the two lesions, with a sufficient extent to allow all the investigations. * subject with i, ii, iii or iv skin phototype (according to fitzpatrick's scale). * for woman of childbearing potential (defined as all women physiologically capable of becoming pregnant): negative urine pregnancy test at inclusion visit. use of a highly effective method of birth control\* during the study. \* a highly effective method of birth control is defined as one which results in a low failure rate (less than 1%) when used consistently and correctly, such as implants, combined oral contraceptives, intrauterine device, double barrier methods (e.g. condom with spermicide), sexual abstinence or vasectomized partner. * subject with health insurance coverage according to local regulation. * subject having given his written informed consent. exclusion criteria: * subject having a known hypersensitivity, allergy or contraindication to any ingredients contained within the investigational product or placebo. * subject having exposed his skin to natural or artificial uv within 8 weeks prior to the inclusion visit or intending to expose his skin during the study. * subject having performed phototherapy within 8 weeks prior to the inclusion visit or intending to perform phototherapy during the study. * subject having performed another physical treatment (e.g radiotherapy...) on the investigational areas within 6 months prior to the inclusion visit or intending to perform it during the study. * subject treated with systemic non-steroidal anti-inflammatory drugs (≥3 days) within 1 week before the inclusion visit. * subject treated with biological immunosuppressive drugs within 12 weeks prior to the inclusion visit or intending to be treated with it during the study. * subject treated with non-biological immunosuppressive drugs within 4 weeks prior to the inclusion visit or intending to be treated with it during the study. * subject treated with systemic corticoids within 1 week prior to the inclusion visit or planed during the study. * subject treated with systemic antibiotics within 7 days prior to the inclusion visit or planed during the study. * subject having applied topical immunomodulators, non-steroidal anti-inflammatory, corticoids or antihistamines on investigational limbs within 1 weeks prior to the inclusion visit. * subject having applied topical antibiotics or disinfectants on investigational limbs within 2 weeks prior to the inclusion visit. * subject having applied any other topical and/or care product after the last grooming prior to the inclusion visit. * subject having applied water or care product (except hands cleaning) within 12 hours prior to the inclusion visit. * subject having started, modified or stopped any other treatment/product within 4 weeks prior to the inclusion visit or intending to do so during the study that according to the investigator's judgment, could interfere with study results. * subject having significant medical condition that according to the investigator's judgment, deems inappropriate for study participation (e.g present or past malignancy, present or past skin condition...). * subject having significant dermatological condition or sign (e.g disease, scare, abundant hairiness, tanning mark...) that according to the investigator's judgment, could limit the observations or/and interfere with the interpretations. * subject taking part or having participated in another clinical study within 2 weeks prior to the inclusion visit. * subject under legal guardianship or incapacitation. * subject linguistically or psychologically unable of signing informed consent form and unable to comply with the protocol requirements according to the investigator's judgment.